Neurocrine Biosciences
NBIXNASDAQSmall molecule drug development targeting neurological and endocrine disorders
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-08-28. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
Filing figures as of June 30, 2026 · text updated 2026-08-28 · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
NBIX filings on EDGAR →Cash & investments
$482M
at June 30, 2026 (10-Q)
Quarterly operating burn
No burn
operating cash flow positive, Jan–Jun 2026
Cash runway
—
not a runway: funded by operations
Shares outstanding
101.6M
cover page of the latest filing
Read from NBIX's XBRL financial data; latest filing July 31, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Commercial.
Upcoming catalysts
No upcoming catalyst for Neurocrine Biosciences has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| NBI-1065845 | Major Depressive Disorder (MDD) | Phase 3 | Q4 2026 | ▼ |
| NBI-1117568 | Bipolar I Disorder with Mania | Phase 2 | Q4 2026 | ▼ |
| NBI-1117570 | Schizophrenia | Phase 2 | Q1 2027 | ▼ |
| NBI-1070770 | Major Depressive Disorder (MDD) | Phase 2 | Data already completed; results pending publication | ▼ |
| NBI-1065890 | Tardive Dyskinesia | Phase 2 | Q2 2027 | ▼ |
| Valbenazine | Chorea Associated with Huntington Disease | Approved | Approved by FDA in August 2023 | ▼ |
What does Neurocrine Biosciences do?
Neurocrine Biosciences is a biotech company that focuses on developing drugs for brain and nervous system disorders. They already have a successful drug called Ingrezza that treats a movement disorder called tardive dyskinesia, which brings in over a billion dollars a year. Now they are working on new treatments for depression, bipolar disorder, schizophrenia, and Huntington's disease. The most advanced is a new depression drug that works differently from current ones, and they are running large studies to see if it works. If successful, it could be a big new source of revenue. However, developing brain drugs is very risky - many fail in late-stage trials. Investors should watch for data from these studies, as they could cause big stock moves. The company has a lot of cash, so they can fund these trials without worrying about running out of money soon. Overall, it's a high-risk, high-reward opportunity.
What to watch
Monitor enrollment and completion of phase 3 trials for NBI-1065845 in MDD.
Watch for any safety signals or interim analyses from the ongoing trials.
Track quarterly earnings reports for Ingrezza sales trends and any updates on pipeline.
Follow presentations at major medical conferences like AAN, CTAD, and AD/PD.
Keep an eye on regulatory decisions for competitors that could affect the market landscape.
Investment thesis
High RiskBull case
Neurocrine has a strong commercial foundation with Ingrezza (valbenazine) for tardive dyskinesia, generating over $1.5B in annual sales. The pipeline is deep, with multiple phase 3 programs in major depressive disorder (MDD) using a novel mechanism (NBI-1065845) that could address the high unmet need in depression. The company has a strong balance sheet with $1.5B cash and no near-term debt, providing runway for multiple catalysts. The recent positive phase 2 data for NBI-1070770 in MDD adds further confidence. With an aging population and increasing prevalence of CNS disorders, Neurocrine is well-positioned to become a leader in neuroscience. The management team has a track record of successful development and commercialization, as seen with Ingrezza. If the MDD program succeeds, it could double the company's revenue potential.
Bear case
Neurocrine faces significant risks in its pipeline. The MDD program (NBI-1065845) is in phase 3, but the CNS space is notoriously difficult, with high failure rates. The mechanism of action, while novel, may not show sufficient efficacy or safety compared to existing treatments like SSRIs or ketamine-based therapies. The company is heavily reliant on Ingrezza, which faces patent expiration in the late 2030s, and competition from generics could erode revenue. The phase 2 data for NBI-1070770 was not disclosed in detail, and the program may not advance. Additionally, the company has a high valuation, trading at a premium to peers, which leaves little room for disappointment. Any clinical trial failure could lead to a significant stock drop. Furthermore, regulatory hurdles and reimbursement challenges for new CNS drugs could limit commercial success.
Risk factors
High failure rate in phase 3 CNS trials, particularly for depression.
Competition from established antidepressants and emerging therapies like esketamine and psilocybin.
Dependence on Ingrezza for revenue; patent expiration and generic competition could impact financials.
Regulatory challenges in CNS indications, including the need for long-term safety data.
Potential for clinical holds or safety issues in ongoing trials.
Comparable companies
Sponsored
Get premium NBIX analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you